A Study of the Safety and Immune Response of 2 Doses of a New Shigella Vaccine in Kenyan Adults

NCT02676895 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

74

Enrollment

INDUSTRY

Sponsor class

Conditions

Shigella Sonnei Infection

Interventions

BIOLOGICAL: GVGH S. sonnei (1790GAHB) vaccine 25 μg
BIOLOGICAL: GVGH S. sonnei (1790GAHB) vaccine 100 μg
BIOLOGICAL: Menveo
BIOLOGICAL: Boostrix

Sponsor

GlaxoSmithKline